1,4-Dihydropyridines versus beta-blockers for hypertension: Are either safe for the heart? Frans H. H. Leenen Editorial: Focus on Calcium Antagonists Pages: 397 - 402
Calcium channel antagonists in the modern era of coronary thrombolysis: Benefit or detriment? John A. FoleyRichard C. Becker Editorial: Focus on Calcium Antagonists Pages: 403 - 407
Controversies concerning calcium antagonists Paul R. Lichtlen Editorial: Focus on Calcium Antagonists Pages: 409 - 412
Calcium channel blocker debate: True lies? Jonathan LeorAlex Battler Editorial: Focus on Calcium Antagonists Pages: 413 - 415
Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals Claudio NapoliMassimo ChiarielloGiuseppe Ambrosio Pharmacology: New Aspects of Calcium Antagonists Pages: 417 - 424
Effects of felodipine on the ischemic heart: Insight into the mechanism of cytoprotection R. FerrariA. CargnoniC. Ceconi Pharmacology: New Aspects of Calcium Antagonists Pages: 425 - 437
Calcium antagonists and endothelial function: Focus on nitric oxide and endothelin Théophile GodfraindSalvatore Salomone Pharmacology: New Aspects of Calcium Antagonists Pages: 439 - 446
Delay by a calcium antagonist, amlodipine, of the onset of primary ventricular fibrillation in myocardial ischemia Quadiri TimourBernard Bui-XuanJean-François Aupetit Pharmacology: New Aspects of Calcium Antagonists Pages: 447 - 454
Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease Lionel H. Opie Therapy: Should Calcium Antagonists Be Among the First-Line Drugs? Pages: 455 - 461
Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective Curt D. FurbergBruce M. Psaty Therapy: Should Calcium Antagonists Be Among the First-Line Drugs? Pages: 463 - 466
The STONE study (Shanghai Trial of Hypertension in the Elderly): A meeting report Meeting Report: STONE Study Pages: 467 - 468
Effect of ACE inhibitors on endothelial dysfunction: Unanswered questions and implications for further investigation and therapy Bertram Pitt Coronary Artery Disease: Editorial Pages: 469 - 473
Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: Results of SHIPS (SHIga Pravastatin Study) Yasuyuki NakamuraOsamu Yamaokathe SHIga Pravastatin Study (SHIPS) Group Statins and Restenosis Pages: 475 - 483
Five-year mortality after acute myocardial infarction in relation to previous history, level of initial care, complications in hospital, and medication at discharge Johan HerlitzAngela BångBjörn W. Karlson Myocardial Infarction: Long Term Mortality Pages: 485 - 490